%0 Journal Article %T Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study %A Bloise %A Walter %A Mimura %A Lidia Yuri %A Moura %A Janete %A Nicolau %A Wilian %J Arquivos Brasileiros de Endocrinologia & Metabologia %D 2011 %I Sociedade Brasileira de Endocrinologia e Metabologia %R 10.1590/S0004-27302011000900004 %X objective: to report the use of sodium diclofenac, an antagonist of ppar-gamma and cyclooxigenase-2 (cox-2) inhibitor in the treatment of mild to moderate graves' ophthalmopathy. subjects and methods: thirteen patients with clinical activity score (cas) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 ¡À 3.4) with oral sodium diclofenac, 50 mg every 12 hours. results: extra-ocular muscle restriction and cas improved significantly, p = 0.003 and = 0.004, respectively. ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. no recurrence was found after interruption of treatment. conclusions: treatment of moderate graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study. %K moderate graves' ophtalmopathy %K treatment %K sodium diclofenac %K ppar-gamma %K cyclooxigenase-2. %U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0004-27302011000900004&lng=en&nrm=iso&tlng=en